The present invention provides among other things compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein salt and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.